- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03586557
Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Definition:
This will be a parallel designed, open-labeled, randomized add-on comparison study between 1) intravenous high dose corticosteroids combined with plasma exchange (PE) and 2) merely intravenous high dose corticosteroids followed subsequent taper of the improvement of optic nerve function in acute aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) positive optic neuritis. The investigators will compare assessments at baseline with those at one, three and six months post treatments.
Patients:
Subjects will be recruited from in-patients who were diagnosed as AQP4-IgG positive optic neuritis in Neuro-Ophthalmology Department in People's Liberation of Army General Hospital (PLAGH) in Beijing, China.
Eligible participants should have inaugural or recurrent unilateral or bilateral optic neuritis attack(s) within 30 days from the first symptom onset. Only affected eyes with VA less than 20/200 at baseline will be included in the study. All of the participants have to have positive serum AQP4-IgG. Enrollment will be allowed irrespective of whether a previous diagnosis of neuromyelitis optica spectrum disorders (NMOSD) was made.
Participants will be randomly assigned (1:1) to exclusively intravenous corticosteroid (CS group) or sequential intravenous corticosteroid and PE( CS and PE group) .
All participants will receive intravenous corticosteroid (1g of methylprednisolone per day for 3~5days, and subsequent taper). The treatment will be started as soon as the participant is admitted to the hospital. The participants in CS and PE group will receive add-on five consecutive PE every other day performed in the ward.
Primary and secondary endpoints:
The primary endpoint will be the value of visual acuity (VA ) at end of follow-up (6 months) in the affected eyes. VA was assessed separately for each eye using Snellen's test chart at baseline, one, three and six months, and was converted to LogMAR for calculation of the mean visual acuity. If the patient has a relapse during the follow-up, the last VA recorded before the relapse will be the final VA outcome of the patient.
Optical Coherence Tomography (OCT) parameters assessed at months 6 will be another primary endpoint. OCT will be performed with spectrum domain OCT (SD-OCT) (Carl Zeiss 5000). Peripapillary retinal nerve fiber layer (pRNFL), macular retinal thickness and macular Ganglion Cell Layer + inner plexiform layer (mGCIPL) will be measured by one skilled technician at the condition of dilated pupil to avoid bias of measurement. Parameters above will be recorded thereafter.
Secondary endpoints will study the numbers of relapses during the follow-up of 6 months, optic nerve conduction velocity measured by Flash Visual Evoked Potential (FVEP) at the end of follow-up (6 months). FVEP will be recorded by visual electro-physiology equipment (Roland RETI-Port/Scan 21). The same technician will perform all the assessments for all the patients to avoid bias of measurement. A final latency assessment was analysed at study end.
Titer of serum AQP4-IgG within 1 month after their attack and six months after treatment will be recorded. Orbital MRI will be assessed and compared if it is necessary.
Security indexes:
Safety assessment at screening,baseline,one , three, and six month are: physical examination and vital signs including blood pressure (BP), heart rate (HR). Hematology and blood chemistry will be assessed as well. blood routine test, coagulation Test, and serum electrolyte will be tested during the PE treatment and followed up at one, three and six months. Allergies during PE treatment will be recorded by doctors. Patients experiencing severe adverse events would be remove from the treatment arm. However, patients with slight or medium adverse events should complete their PE treatment unless they require to quit.
Sample size:
The estimated mean VA outcome of AQP4-IgG positive optic neuritis 6 months after its attack is expected to be about 1.4 (LogMAR) with its standard deviation (SD) around 1.3 (LogMAR), based on 2 observation reports. Another observational study found that mean VA outcome after PE combined corticosteroid treated AQP4-IgG positive optic neuritis was 0.75 (LogMAR). The investigators assume that to achieve 80% power at 5% significance level, using a parallel design, the sample size needs to be 64 cases per group and 128 in all. By accounting for 10% patients potentially withdrawing consent or being lost to follow-up over the course of the study, the final sample size will be increased to 71 cases per arm and 142 patients in all.
Planned Statistical Analysis:
The primary analysis will be intention-to-treat. The outcome of the superiority clinical trial will be assessed based on a two-sided 95% confidence interval around the mean VA and OCT outcome, showing a credible range for true difference between merely corticosteroid and corticosteroid combined PE treatment.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shihui Wei, MD
- Phone Number: +86 13910079431
- Email: weishihui706@hotmail.com
Study Contact Backup
- Name: Mo Yang, PhD
- Phone Number: +86 18310098349
- Email: doctoryangmo@icloud.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100853
- Recruiting
- People's Liberation of Army General Hospital (PLAGH)
-
Contact:
- Shihui Wei, MD
- Phone Number: +86-13910079431
- Email: weishihui706@hotmail.com
-
Contact:
- Mo Yang, PhD
- Phone Number: +86-18310098349
- Email: doctoryangmo@icloud.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 to 70 years old
- Serum AQP4-IgG positive optic neuritis
- Patients must have their VA less than 20/200
- Course of disease is less than 1 month
- Patients must provide written informed consent
Exclusion Criteria:
- Females who are pregnancy
- Patients who are severely allergic to plasma or albumin
- Patients who have systemic disease and can not accept PE
- Patients with a tendency to thrombus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Corticosteroid & Plasma Exchange
1000mg intravenous methylprednisolone daily for 3~5 days and subsequent taper, combined with plasma exchange every other day for five times in all
|
High-dose intravenous methylprednisolone 1000mg 3~5 days and subsequent taper, combined simultaneous plasma exchange 5 times in all
Other Names:
|
Active Comparator: Corticosteroid
1000mg intravenous methylprednisolone daily for 3~5 days, and subsequent corticosteroid decrement.
|
High-dose intravenous methylprednisolone 1000mg 3~5 days and subsequent taper
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Acuity (LogMAR)
Time Frame: from baseline to 6 months
|
the differences in Visual Acuity outcomes between treatment arm and control arm
|
from baseline to 6 months
|
Change in OCT parameters over time
Time Frame: baseline to 6 months
|
Difference in mean thickness of peripapillary retinal nerve fiber layer and macular Ganglion Cell Complex between treatment group and control group
|
baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Flash Visual Evoked Potential over time
Time Frame: baseline to 6 month
|
Difference in P2 peak time and value between treatment group and control group
|
baseline to 6 month
|
rate of recurrence over time
Time Frame: baseline to 6 months
|
the differences in rate of recurrence (number of recurrence patients / number of patients in their arms) between treatment group and control group
|
baseline to 6 months
|
change in serum AQP4-IgG titer over time
Time Frame: baseline to 6 months
|
compare the different changes in serum AQP4-IgG titer (before treatment and 6 months follow-up) between PE combined corticosteroid group and only corticosteroid group
|
baseline to 6 months
|
orbital MRI
Time Frame: baseline to 6 months
|
orbital MRI will be assessed if it is necessary
|
baseline to 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Pressure
Time Frame: baseline, during PE treatment and followed up at one, three and six months
|
the change of Blood Pressure at baseline, during PE treatment and follow up
|
baseline, during PE treatment and followed up at one, three and six months
|
Heart Rate
Time Frame: baseline, during PE treatment and followed up at one, three and six months
|
the change of Heart Rate at baseline, during PE treatment and follow up
|
baseline, during PE treatment and followed up at one, three and six months
|
Rooting Blood Test
Time Frame: baseline, during PE treatment and followed up at one, three and six months
|
the change of Rooting Blood Test outcome at baseline, during PE treatment and follow up
|
baseline, during PE treatment and followed up at one, three and six months
|
Coagulation test
Time Frame: baseline, during PE treatment and followed up at one, three and six months
|
the change of Coagulation test outcome at baseline, during PE treatment and follow up
|
baseline, during PE treatment and followed up at one, three and six months
|
Serum electrolyte
Time Frame: baseline, during PE treatment and followed up at one, three and six months
|
the change of Serum electrolyte at baseline, during PE treatment and follow up
|
baseline, during PE treatment and followed up at one, three and six months
|
side effects
Time Frame: baseline to 6 months
|
record the side effects during the period of PE treatment
|
baseline to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Huanfen Zhou, PhD, Chinese PLA General Hospital
- Principal Investigator: Quangang Xu, PhD, Chinese PLA General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PETON
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Optic Neuritis
-
Medical University of ViennaUnknownOptic; Neuritis, With DemyelinationAustria
-
BiogenCompletedAcute Optic NeuritisSweden, Australia, Italy, Spain, United Kingdom, Germany, Belgium, Denmark, Hungary, Czech Republic, Canada
-
Novartis PharmaceuticalsTerminatedAcute Demylelinating Optic NeuritisUnited States, Spain
-
BiogenCompletedAcute Optic NeuritisSweden, Spain, United Kingdom, Germany, Canada, Denmark, Hungary, Belgium, Czechia, Australia, Italy
-
Accure TherapeuticsSimbec ResearchCompletedOptic Neuritis | Optic; Neuritis, With DemyelinationUnited Kingdom
-
OculisNeurotrialsRecruitingOptic Neuritis | Optic; Neuritis, With DemyelinationFrance
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University of ZurichUniversity Hospital, Zürich; Swiss MS Society; Data Management, Clinical Trials...TerminatedAcute Autoimmune Inflammatory Optic NeuritisSwitzerland
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Xiujuan ZhaoUnknown
Clinical Trials on Corticosteroid & Plasma exchange
-
London Health Sciences CentreWithdrawnPurpura, Thrombotic Thrombocytopenic | Hemolytic Uremic SyndromeCanada
-
London Health Sciences CentreCanadian Institutes of Health Research (CIHR); The Kidney Foundation of CanadaCompletedMultiple Myeloma | Acute Renal FailureCanada
-
Peking University Third HospitalNot yet recruitingPregnancy-related Thrombotic Microangiopathies
-
Heidelberg UniversityTerminated
-
Mayo ClinicTerumo BCTCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder | Recurrent Idiopathic Longitudinally Extensive Transverse MyelitisUnited States
-
Larkin Community HospitalUnknown
-
Forsyth Medical CenterNot yet recruiting
-
Alberta Health Services, CalgaryRecruiting
-
University College, LondonUnknown
-
Novacescu AlexandruUniversity of Medicine and Pharmacy "Victor Babes" TimisoaraCompletedAcute Respiratory Distress Syndrome | COVID-19 Pneumonia | COVID-19 Respiratory Infection | Acute Respiratory FailureRomania